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Abstract
Background: Quantitative results of cardiovascular magnetic resonance (CMR) image analysis influence clinical
decision making. Image analysis is performed based on dedicated software. The manufacturers provide different
analysis tools whose algorithms are often unknown. The aim of this study was to evaluate the impact of software
on quantification of left ventricular (LV) assessment, 2D flow measurement and T1- and T2-parametric mapping.
Methods: Thirty-one data sets of patients who underwent a CMR Scan on 1.5 T were analyzed using three different
software (Circle CVI: cvi42, Siemens Healthineers: Argus, Medis: Qmass/Qflow) by one reader blinded to former results.
Cine steady state free precession short axis images were analyzed regarding LV ejection fraction (EF), end-systolic and
end-diastolic volume (ESV, EDV) and LV mass. Phase-contrast magnetic resonance images were evaluated for forward
stroke volume (SV) and peak velocity (Vmax). Pixel-wise generated native T1- and T2-maps were used to assess T1- and
T2-time. Forty-five data sets were evaluated twice (15 per software) for intraobserver analysis. Equivalence was
considered if the confidence interval of a paired assessment of two sofware was within a tolerance interval
defined by ±1.96 highest standard deviation obtained by intraobserver analysis.
Results: For each parameter, thirty data sets could be analyzed with all three software. All three software (A/B, A/C,
B/C) were considered equivalent for LV EF, EDV, ESV, mass, 2D flow SV and T2-time. Differences between software were
detected in flow measurement for Vmax and in parametric mapping for T1-time. For Vmax, equivalence was given
between software A and C and for T1-time equivalence was given between software B and C.
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Conclusion: Software had no impact on quantitative results of LV assessment, T2-time and SV based on 2D flow. In
contrast to that, Vmax and T1-time may be influenced by software. CMR reports should contain the name and version
of the software applied for image analysis to avoid misinterpretation upon follow-up and research examinations.
Trial registration: ISRCTN12210850. Registered 14 July 2017, retrospectively registered.
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Background
In the past years, cardiovascular magnetic resonance Im-
aging (CMR) has emerged as a broadly applied imaging
modality in cardiac diagnostics [1]. Due to its high ac-
curacy and reproducibility, CMR is considered as gold
standard for evaluation of left ventricular (LV) function
[2]. CMR is the recommended method to assess cardiac
function and hemodynamics especially when transtho-
racic echocardiography is limited [3]. In addition to
mere functional assessment, non-invasive tissue differen-
tiation represents CMR’s unique feature [4]. Clinical
decision-making is often based on quantification, i.e. the
placement of an implantable cardiac defibrillator de-
pends on quantified LV function or valve replacement
on quantitative flow assessment [5–7]. Therefore, accur-
ate and reliable quantification is essential for correct
diagnosis and adequate treatment. Technical aspects
such as field strength, vendor platforms and imaging
protocol influence CMR results [8–12]. The Society for
Cardiovascular Magnetic Resonance (SCMR) published
not only standardized protocols for image acquisition
and interpretation, but also guidelines for reporting
which propose to report scanner type, sequences used
and study quality [13–15]. Interestingly, it is not sug-
gested to report the software used [15]. CMR image ana-
lysis is performed on dedicated commercial and
non-commercial software solutions. They often differ
within and between sites. Quantitative analysis is mostly
based on manually contouring or manually correction of
semi-automatic segmented regions of interest (ROI) in
CMR images. For LV volumetry and flow quantification,
the contour relies on the definition of a whole pixel or
subpixel depending on the software. In case of parametric
mapping, not all software providers do have a specific tool.
A recent study reported that software used for myocardial
perfusion analysis is not interchangeable and reliable results
were only achieved within the same software [16]. In con-
trast to this, statistically significant differences were found in
analysis of T2* mapping between two software which were
considered to be without any effect on clinical decision
making [17]. Other groups found a strong correlation and
no significant differences between software for LV assess-
ment [18, 19]. Software comparison for flow measurement
was only done in a small number of patients [20]. The im-
pact of the software-dependent approaches of contour
modification on results is unknown and mathematical cal-
culation and extrapolation remain reserved to the vendors.
The aim of the present study was to investigate the
equivalence of three commercially available software
used at our site for assessment of LV, 2D flow and T1-
and T2-parametric mapping. We hypothesized that
mean differences between software are smaller than
intraobserver variability and hence, software can be con-
sidered as equivalent.
Methods
Patient data sets
For logistical reasons, we chose at the beginning of this
study the first available data sets of patients with histo-
logically confirmed soft tissue sarcoma planned for
anthracycline-based chemotherapy from an on-going
study of our working group (ISRCTN12210850) [21].
Exclusion criteria were chronic renal failure (estimated
glomerular filtration rate < 30mL/m2), cardiac metasta-
ses, known incompatibility for gadolinium contrast
media and contraindication for CMR. We had to exclude
short axis images (SAX) in one patient as they were not
recorded continuously, T1-map in one patient due to an
artifact and flow in one patient due to aliasing in flow
measurement. In order to still match the required num-
ber of analyzed data, we included a 31st patient for ana-
lysis of SAX, T1-time and flow. A total of 31 data sets of
patients (16 male, details see Table 1) were analyzed.
Table 1 Patient characteristics
Variables Patients (n = 31)
Age [years] 60 ± 14
Height [cm] 172.7 ± 9.5
Weight [kg] 80.1 ± 18.9
Body surface area [m2] 1.95 ± 0.27
Systolic blood pressure [mmHg] 119.3 ± 17.4
Diastolic blood pressure [mmHg] 71.7 ± 10.9
Heart rate [bpm] 68.9 ± 18.1
Values are presented as mean ± standard deviation
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The population suffered from different co-morbidities.
In detail, 15 patients (48%) had arterial hypertension, 1 pa-
tient (3%) had coronary artery disease and 6 patients had
diabetes mellitus type II (19%). Eleven patients (36%) re-
ceived anthracycline-based chemotherapy (> 300mg/m2
doxorubicin-equivalent cumulative dose) prior to the
study. Ethical approval was given for the mentioned
study by the local ethics committee of Charité
Medical University Berlin (approval number EA1/262/
14). All patients gave their written informed consent
before participating in the study.
CMR imaging protocol
All CMR examinations were performed using a 1.5 Tesla
scanner (Magnetom Avanto Fit, Siemens Healthineers,
Erlangen, Germany). Protocol and slice planning were
identical in all cases according to institutional standards.
In short, retrospective electrocardiographic (ECG) gated
balanced steady state free precession (bSSFP) cine images
covering the whole LV from basis to apex were obtained
without gap in a breath-hold technique (repetition time
46.34ms, echo time 1.44ms, voxel size 2.0 × 2.0 × 7.0
mm3, flip angle 80 degrees). Segmented gradient-echo
phase contrast CMR (PC-CMR) was performed at the
sinotubular junction of the ascending aorta. The velocity
encoding range was set at 150 cm/s in a through-plane
direction [9]. Native T1- and T2-mapping data were
obtained in one midventricular short axis as previ-
ously described [4].
Post-processing software packages
Three software packages were used for image analysis
and quantitative assessment according to current institu-
tional standards between June and December 2016 [13].
All data sets were analyzed by one reader (L.Z.) blinded
to former quantitative results using Circle Cardiovascular
Imaging: cvi42 version 5.3.2 (Calgary, Canada), (software
A); Siemens Healthineers: Classic Argus (Argus viewer,
Argus LV function and Argus flow) on SyngoMMWP
version VE53A acquisition work place, (software B); and
Medis medical imaging systems: Medis Suite 2.1 with the
applications Qmass and Qflow version 8.1 (Leiden,
Netherlands), (software C). We analyzed software using
the default settings. The software surfaces are presented
in Fig. 1. Forty-five data sets randomly selected were
analyzed twice (15 per software) for intraobserver
analysis.
Left ventricular assessment
For LV assessment we used cvi42 heart function [22],
Argus LV function [23] and Qmass ventricular function
[24]. Endo- and epicardial borders were contoured
manually in short axis cine images (SAX) at end-diastole
and end-systole. The basal slice was included in the
analysis if at least 50% of blood volume was surrounded
by myocardium. Papillary muscles were excluded and
considered part of the blood pool. If available, contour
smoothing was applied. Quality control of the contours
was performed in the movie mode. Ejection fraction (EF
in %) and myocardial mass (Mass in g), end-systolic and
end-diastolic volume (ESV and EDV, respectively, in ml)
were recorded [25].
Flow measurement
For 2D flow assessment, we used cvi42 Flow [26], Argus
Flow [27] and Qflow PC Flow [28]. The ascending aorta
was contoured in the magnitude image with the sharpest
blood/tissue contrast. Contours were propagated to
phase contrast images in all temporal phases, corrected
manually and controlled carefully. Peak velocity (Vmax
in cm/s) was measured in all software and forward
stroke volume (SV in ml) was calculated automatically
in function of the vessel area in all phases [29].
Parametric mapping
For T1 and T2 mapping the procedure was identical in
cvi42 (using T1- and T2-tool) [30, 31] and Qmass (using
time signal intensity mode) [32]. Endo- and epicardial
limits were delineated and corrected in all 8 raw images
for T1-mapping or 3 raw images for T2-mapping, copied
into the scanner generated pixel maps and corrected
again if necessary. In Argus viewer [33], a ROI was
drawn around the myocardium in all colored pixel-wise
maps with the same procedure for all studies. Segment-
based global T1- and T2-times (in ms) and area (if avail-
able) were recorded [34, 35].
Statistical analysis
The sample size calculation for the equivalence test was
based on reference values obtained with cvi42 in our
working group and from literature assuming that the
distribution of the available data is comparable to other
software types [9, 36, 37]. The equivalence margin was
set to the 95% tolerance interval of the intraobserver dif-
ference with 95% coverage, such that two software sys-
tems would be considered equivalent if their deviations
would be within the limits of 95% of the deviances gen-
erated by one observer performing repeated measures
with the same software. It was assumed that the stand-
ard deviation (SD) of each software would be equal to
the intraobserver variability. Based on a power of 0.9
and a Bonferroni-corrected α-level of 0.017 correcting
for three tests, 30 patients were found to be sufficient
even for the conservative assumption of a correlation
of 0.2 between measurements of two different soft-
ware. PASS, version 11, was used for sample size cal-
culation [38].
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Normality was checked based on visual inspection of the
data using Quantile-Quantile-plots (QQ-plots). No strong
deviations from normal distribution were noted thus para-
metric methods were used. The Pearson’s correlation coeffi-
cient (r) was calculated for correlation analysis and
Bland-Altman plots were generated to assess the bias
(mean difference) and the 95% limits of agreement between
each pair of software for each parameter. Equivalence limits
were determined as ±1.96 maximum intraobserver SD vari-
ability across the three software, which corresponds to the
largest observed 95% tolerance interval with 95% coverage
of repeated measurements with the same software. Follow-
ing the approach outlined by Walker and Nowacki [39],
Bonferroni corrected confidence intervals were constructed
using α = 0.05/3 = 0.017, thus leading to (1–2α)*100% =
96.7% confidence intervals. These were obtained for the
paired assessments of two software and equivalence was
concluded when the confidence interval was completely
within the limits of equivalence. Testing the null hypothesis
of no difference between software was based on a test with
shifted null hypothesis where the shift equaled the respect-
ive limits of equivalence. As the results of an equivalence
test by CI is only binary (yes/no), no p-values were given.
Area of T1- and T2-mapping was recorded if applic-
able and compared for differences by paired t-test
with α = 0.05. Statistical analysis was performed by
Graph Pad Prism 6, version 6.0.7 for windows [40].
Results
For each parameter 30 data sets were available and could
be analyzed with each software (Fig. 2 and Table 2).
Left ventricular assessment
All software showed a strong positive correlation for
EF (r software A/B: 0.940, software A/C: 0.965, soft-
ware B/C: 0.951), mass (r software A/B: 0.975, software
A/C: 0.975, software B/C: 0.974), EDV (r software A/B:
0.994, software A/C: 0.996, software B/C: 0.995) and ESV
(r software A/B: 0.994, software A/C: 0.997, software
B/C: 0.996). For EF, Bland-Altman analysis revealed
Fig. 1 Presentation of software surfaces. Screenshots of cvi42, Argus and Medis Suite used for image analysis for left ventricular assessment,
2D flow measurement and T1- and T2-parametric mapping
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narrowest limits of agreement between software A/C
(Fig. 3b). Smallest bias but widest limits of agreement
were found between software A/B (Fig. 3a). Comparing
software B/C, a rising difference with increasing mean is
shown (Fig. 3c). For mass, bias of software A/B was more
than twice and B/C more than three times higher com-
pared to software A/C (Fig. 3d-f). For EDV and ESV, nar-
rowest limits of agreement were found between software
Fig. 2 Single values obtained for each patient with each software for left ventricular assessment (a-d), 2D flow (e, f) and parametric mapping
(g, h). EF: ejection fraction, EDV end-systolic volume, ESV end-diastolic volume, Vmax: peak velocity, SV: stroke volume. Blue dot: Software
A; black square: Software B; red triangle: Software C
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A/C, but smallest bias was detected between software
B/C (Fig. 4a-f ).
Flow measurement
All software showed a very strong positive correlation
for Vmax (r: software A/B: 0.996, software A/C: 1.0, soft-
ware B/C 0.996) and SV (r: S software A/B: 0.989, soft-
ware A/C: 0.992, software B/C 0.986). For Vmax, bias of
software A/C was close to zero and presented narrowest
limits of agreement (Fig. 5b). Software B showed lower
Vmax compared to software A and software C (Fig. 5a,
c). For SV, smallest bias was found between software A/
B (Fig. 5d). Software C showed lower SV compared to
software A and software B (Fig. 5e, f ).
Parametric mapping
Software B/C showed highest correlation for T1-time (r: S
software W A/B: 0.903, software A/C: 0.891, software B/C
0.961) and for T2-time (r: software A/B: 0.897, software A/C
Fig. 3 Bland-Altman plots of LV function (EF) and LV mass for agreement between software A and B (a, d), software A and C (b, e) and software
B and C (c, f). Dashed lines indicate mean difference, dotted lines indicate limits of agreement
Table 2 Results of left ventricular assessment, 2D Flow and
parametric mapping per software (A, B, C)
Software A Software B Software C
Left ventricular assessment
Ejection Fraction [%] 59.5 ± 8.6 60.1 ± 9.8 61.1 ± 9.4
Mass [g] 90.8 ± 29.1 95.2 ± 27.3 89.0 ± 26.5
End-diastolic volume
[ml]
154.4 ± 51.7 149.6 ± 49.7 151.5 ± 51.1
End-systolic volume [ml] 65.8 ± 40.0 63.4 ± 39.8 62.6 ± 40.4
2D Flow measurement
Vmax [cm/s] 98.0 ± 29.6 92.8 ± 27.4 98.0 ± 29.6
Stroke Volume [ml] 75.7 ± 19.2 75.3 ± 18.5 72.5 ± 18.4
Parametric mapping
T1-time [ms] 1008.1 ± 51.9 1030.8 ± 44.5 1023.2 ± 48.8
T2-time [ms] 54.2 ± 3.9 55.0 ± 3.1 54.9 ± 3.0
Values are presented as mean ± standard deviation
EF ejection fraction, EDV end-systolic volume, ESV end-diastolic volume, Vmax
peak velocity, SV stroke volume
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0.912, software B/C 0.931). Software A had longer T1- and
T2-time and best agreement was detected between software
B/C (Fig. 6a-f). The measured area was significantly smaller
in software A compared to software B for both, T1- and
T2-time (p < 0.001, respectively). Within one software, the
measured area did not differ between first and second meas-
urement of T1- and T2-time (p > 0.05, respectively).
Equivalence testing
Equivalence limits for the differences between software
for each parameter were based on the highest SD ob-
tained by intraobserver analysis and were derived as
±1.96 SD (Table 3, Additional files 1 and 2). Software B
showed the highest SD for all parameters except for
mass and ESV (software A). For EF, mass, EDV, ESV, SV
and T2-time, the Bonferroni-corrected confidence inter-
vals (indicated as black lines in Fig. 7) of all software
comparisons were completely contained within the
equivalence limits (indicated as grey shaded area in
Fig. 7), indicating that software A, B and C could be con-
sidered to be equivalent for these parameters (Fig. 7a, b, d,
f ). For Vmax, software A/C (CI -0.1 to 0.0) were equiva-
lent, (Fig. 7c). In contrast to that, the confidence intervals
of the comparisons of software A/B (CI 3.8 to 6.5) and B/
C (CI -6.6 to − 3.8) were completely outside of equiva-
lence limits (− 0.2 to 0.2), indicating no equivalence be-
tween software A and B as well as between software B and
C. For T1-time, equivalence was given between software B
and C (CI 1.9 to 13.2) as illustrated in Fig. 7e. The lower
confidence intervals of comparisons of software A/B (CI
-32.0 to − 13.3) and A/C (CI -25.0 to − 5.3) were margin-
ally outside of the equivalence limits (CI-24.5 to 24.5) sig-
nifying that there was not sufficient evidence to claim
equivalence.
Discussion
Quantification is a basic requirement for cardiovascular
decision making and several parameters in CMR depend
Fig. 4 Bland-Altman plots of LV end-diastolic (EDV) and end-systolic volume (ESV) for agreement between software A and B (a, d), software A
and C (b, e) and software B and C (c, f). Dashed lines indicate mean difference, dotted lines indicate limits of agreement
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on reliable and robust values. To the best of our know-
ledge, this is the first study comparing three CMR ana-
lysis software for quantification of LV 2D flow and T1
and T2 parametric mapping. Main findings were: (i) all
three software were equivalent for LV assessment (EF,
EDV, ESV and mass), (ii) all three software were equiva-
lent for SV, but only two software for Vmax, (iii) equiva-
lence was given for all software in quantification of
T2-time, but only two software for T1-time.
It is well known that different post-processing SW are
used world-wide in clinical routine and research. They dif-
fer e.g. regarding pixel definition settings, contour detec-
tion and other algorithms. Each pixel of a cardiac image
displayed by the post-processing software provides infor-
mation about its size and specific value, such as maximum
velocity in case of flow measurement or T1-time in case
of T1-mapping. For quantitative image analysis contours
intersect pixels. Depending on the software type, different
pixel inclusion methods for calculations can be used, e.g.
to involve the pixel partly or entirely. In a clinical setting it
is crucial to know if these potential differences could im-
pact the results. Previous studies compared the relation
between software using correlations, intra-class-coefficient
and significant differences. We applied an equivalence
testing approach using the intraobserver variability to de-
fine equivalence margins to identify deviations between
software. In the present study there is no impact of scan
procedure related technical influences [21] as we analyzed
the same data sets with all three software. The discussion
of the results is based on the findings of the particular
software versions, we have used. All vendors were
open-minded for discussion and adaption.
For LV assessment, all three software showed a high
correlation and equivalence for LV EF, EDV, ESV and
mass. Our results are supported by previous studies
using different software. Messali et al. revealed a high
correlation of LV function and volume without significant
differences between ViewForum (Philips) and Argus in 46
Fig. 5 Bland-Altman plots of peak velocity (Vmax) and stroke volume (SV) for agreement between software A and B (a, d), software A and C (b,
e) and software B and C (c, f). Dashed lines indicate mean difference, dotted lines indicate limits of agreement
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patients [19]. Kara et al. demonstrated a high correlation
between LV tutorials (Cardiovascular Imaging Solutions)
and Argus in 40 patients with known or suspected coron-
ary artery disease. Additionally, they compared CMR
software with other modalities like CT and 2D echocardi-
ography, but only for EDV they could show a stronger
correlation between CMR tools and CT rather than the
two CMR software. Another group compared image ana-
lysis of 15 healthy subjects between one scanner providing
MASS and one scanner providing Argus and did not find
significant differences within one observer [41]. Neverthe-
less, CMR image segmentation is reader dependent and
LV quantification differs even between expert readers
which emphasizes the need for standardization [42]. In
our study, we assumed that a range within software could
be declared as equivalent, however, this range would de-
pend on the reader’s precision. Still, our intraobserver bias
was comparable to former results even though we ex-
cluded papillary muscles from LV mass [36, 43]. In the
Fig. 6 Bland-Altman plots of T1-time and T2-time for agreement between software A and B (a, d), software A and C (b, e) and software B and C
(c, f). Dashed lines indicate mean difference, dotted lines indicate limits of agreement
Table 3 Intraobserver variability for software A, B and C
Software A Software B Software C
Left ventricular assessment
Ejection Fraction [%] −0.2 ± 2.4 −0.5 ± 2.7 0.5 ± 1.6
Mass [g] 2.9 ± 6.8 − 3.4 ± 5.0 − 1.3 ± 3.4
End-diastolic volume [ml] 1.9 ± 5.0 0.6 ± 5.5 − 0.1 ± 3.4
End-systolic volume [ml] 0.6 ± 3.7 0.6 ± 2.9 0.3 ± 2.3
2D Flow measurement
Vmax [cm/s] 0.0 ± 0.0 0.0 ± 0.1 0.0 ± 0.0
Stroke Volume [ml] −1.0 ± 2.1 −1.2 ± 2.3 0.0 ± 1.6
Parametric mapping
T1-time [ms] −9.4 ± 9.0 −4.0 ± 12.5 −0.6 ± 12.2
T2-time [ms] − 0.4 ± 0.9 −0.1 ± 1.6 −0.1 ± 1.1
Intraobserver variability expressed as mean bias ± standard deviation. The
greatest standard deviation among the three software is indicated in bold
EF ejection fraction, EDV end-diastolic volume, ESV end-systolic volume, Vmax
peak velocity, SV stroke volume
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present study, each software calculated volumes in func-
tion of area and slice thickness. As there was no gap
between the SAX slices, interpolation was not necessary.
EF and mass were derived from cardiac volumes. We
conclude that different pixel definitions of the present
software did not substantially influence results of LV volu-
metry. The applied software are interchangeable for LV as-
sessment in this cohort of patients.
Fig. 7 Equivalence testing for LV assessment (a-d), flow measurement (e, f), parametric mapping (g, h). Equivalence of measurements of two
software is shown if the confidence interval for software comparison (indicated as black lines, squares marked upper and lower limits) are
contained within the equivalence limits (tolerance interval marked grey)
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Hemodynamics can be assessed by PC-CMR to evalu-
ate shunt fraction, valve regurgitation or stenosis [3].
We used automatic contour propagation with manual
correction in all three software for comparison of flow
data sets of 30 patients. Boye et al. applied a software
flow analysis procedure in 6 patients with aortic insuffi-
ciency and showed similar results for aortic regurgitant
fraction based on backward/forward SV in four software,
three out of those four were the same as in our study
[20]. Consistently, the present study showed equivalence
for SV between all three software. However, even in
phantom measurements without manual contour correc-
tion they revealed differences in contour propagation
algorithms as they found different velocities among soft-
ware. In our study, intraobserver analysis of Vmax
showed a high reliability within each software. But, des-
pite accurate corrected anatomical borders, we identified
software B measuring nonequivalent Vmax values com-
pared to other software even when the peak velocity
measuring square was in the same phase and visually at
a similar location within the vessel. This finding is attrib-
uted to different voxel averaging methods, depending on
the software. In software B the default of flow measure-
ment was an averaging including 4 adjacent voxels in
contrast to the other software which preset a single
voxel. Voxel averaging techniques reduce spatial reso-
lution of the measurement and significantly underesti-
mate peak velocity compared to the single voxel
technique with a difference of 7% mean percentage, but
do not influence the flow volume [44]. We found nearly
congruent Vmax values between software A and C,
whereas these software showed the highest bias in SV.
This could be explained by the fact that Vmax is mea-
sured by only one or a few voxel while SV is calculated
as sum of velocities of the voxel within the ROI multi-
plied by the area at each temporal phase [45]. We can-
not exclude small differences in ROI sizes despite
manual border correction among software. However,
ROI size should then substantially affect the SV which
was not the case in this study. Interestingly, the velocity
measuring pixel among two software vendors partly
exceeded the anatomical and delineated border of the
aorta, in turn possibly inducing an incorrect velocity
value for this phase. Therefore, attentive care must be
taken to control outliers and to avoid misalignment.
Other authors analyzed also the impact of different
modalities to assess different anatomical structures
[46–49]. In our opinion, the validation of different
software is warranted at least within an imaging mo-
dality and needs further attention.
CMR enables tissue characterization using parametric
mapping techniques. Myocardial T2-mapping can detect
edema in acute myocardial infarction or inflammation
[37]. Native T1-mapping reflects pathological changes in
both myocardium and interstitium [35, 50]. It allows fur-
ther differentiation of cardiac diseases in LV hypertrophy
and in systemic diseases such as amyloidosis [51, 52].
For T2* analysis, statistically significant but clinically
negligible differences were found between the software
Functool protocol (GE) and the T2* module of Qmass
[17]. In line with this finding, our results indicated that
the present software are not equivalent in quantifying
T1-times. Differences could occur due to different con-
tour drawing procedures and pixel inclusion approaches
that potentially influence precision. This may lead to the
significant smaller area of the ROI in software A than in
software B for both, T1- and T2-quantification. Qmass
and cvi42 provided a tool for endo- and epicardial border
delineation. Argus has no such specific tool yet. How-
ever, within one software, the delineated area was con-
sistent between two measurements. Another explanation
for discrepancies might be the different ranges of the
values for T1- and T2-time. This is supported by the fact
that the relation of our maximum intraobserver SD to
the recently published segment based normal values of
our group was much smaller for T1- than for T2-time
accounting for narrower equivalence limits for T1-time
(the maximum intraobserver SD of ±24.4 ms correlates
to ±2.5% of the published normal value of 980.7 ms for
T1-time, whereas the maximum intraobserver SD ±3.2
ms correlates to ±6.1% of the published normal value of
52.3 ms for T2-time) [4]. Within one software, SD of
intraobserver analysis for T2-time was comparable to
other studies using Qmass and Osirix [37, 53]. The
intraobserver SD of T1-time is in good agreement with
other publications in the literature investigating View-
Forum and cvi42 [4, 10, 11, 54]. However, the range of
published intraobserver values is considerably high. De-
pending on the CMR sequence a correction factor can
be introduced if T1-times have to be calculated using
the software [55]. Therefore, the impact of software on
T1-time quantification should be evaluated in further
studies including other diseases like amyloid and hyper-
trophic cardiomyopathy and at different sites with an ap-
proach to correct for some variations as described for
LV assessment [42].
Limitations
Currently there is a lack of an internationally accepted
gold standard for software, like phantoms for the differ-
ent cardiac structure and function. Therefore, we used
intraobserver variability of an experienced reader as gold
standard to assess equivalence testing. We investigated
only a certain number of SW, being aware that there are
many others on the market. Further, our findings were
specific for the particular software version, knowing that
software packages evolve continuously. We did not
analyze different cardiovascular diseases but among the
Zange et al. Journal of Cardiovascular Magnetic Resonance           (2019) 21:12 Page 11 of 14
selected patients 52% suffered from cardiac alterations.
The potential influence of multiple observers and other
pathologies on the comparability of results from differ-
ent software systems was not considered in this study
but should be subject to continuative analyses.
Conclusion
We could demonstrate exchangeability of cvi42 version
5.6, Classic Argus and Medis Suite 2.1 for LV evaluation,
forward stroke volume in 2D flow measurement and
T2-time in T2 parametric mapping. We conclude that
different pixel inclusion methods of the software do not
substantially affect calculation of the mentioned parame-
ters but might influence results of T1-time. Vessel con-
tours and the peak velocity measuring square in each
phase of flow measurement should be checked carefully,
particularly when contour propagation is used. Software
users should be aware of the current setting of voxel
averaging techniques during flow analysis. Our results
underline the need of standardization and indicate that
the individual analysis software (including version) and
specific settings should be mentioned in clinical reports
to avoid misinterpretation upon follow-up examinations
and to assure comparability of CMR studies.
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